Access Adverse Event (AE) grading in Oncology here: The Common Terminology Criteria for Adverse Events from the National Cancer Institute (NCI)
Reporting Adverse Events
Adverse Events should be reported. Information on reporting can be found at www.hpra.ie. Reporting forms can be found here.
Adverse Events and Patients
The patient should be made aware of the importance of reporting adverse events to their doctor or nurse as soon as they occur so that appropriate care can be given. Please refer to the Keytruda SPC for full management advice for immune-related adverse events.1
Risk Management Materials
Risk Management Materials are available for healthcare professionals who are managing patients that are receiving Keytruda.
If you have not received a copy of these materials, please contact one of our medical information team at MSD Ireland by calling 01 2998700 or click on this link: Contact Us
References
- Keytruda (pembrolizumab) Summary of Product characteristics (SPC). 25mg/ml concentrate for infusion. Last accessed June 2021 https://www.medicines.ie/medicines/keytruda-25-mg-ml-concentrate-for-solution-for-infusion-32596/
